BioSpace News Archive

Sophiris Bio Inc. (Nasdaq: SPHS) (the “Company” or “Sophiris”), today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 5,333,334 of its common shares

HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, today announced a distribution agreement with Charles River’s subsidiary, Vital River, to provide the scientific community in China with direct access to healthy and disease-state human primary cells.

1Q20 Added 20,815 New Subscribers

Total Revenues of $266.9M, up 27% Year-over-year; Subscription Services Revenues of $217.3M, up 28% Year-over-year

Fourth quarter results driven by 10.1% year-over-year growth in home care revenue and operating margin improvement to 17.3%

Mr. Chris Podolsky, Interim Chief Financial Officer, will remain in an advisory capacity to the Company for an appropriate period, to ensure a smooth CFO transition.

ASC40, an orally bioavailable, first-in-class inhibitor of fatty acid synthase, is currently in a global Phase 2 trial in NASH of which the first patient was dosed in late April, 2019 in the USA.